EGFR and biliary tract neoplasm: This clinical trial aims to generate a CAR-EGFR-TGFβR-knockout T by deleting TGF-receptor II using CRISPR/Cas9, to study its anti-tumour activity and safety profiles in EGFR-positive advanced unresectable or metastatic biliary tract cancer, previously treated.